1 Main Capital, a boutique investment firm, released its first-quarter 2025 investor letter. A copy of the letter can be downloaded here. The fund returned (3.6)% net in the first quarter compared to (4.3)% and (9.5)% for the S&P 500 (SPX) and Russell 2000 (RTY). Since its inception in February 2018, the fund has returned annualized net returns of 19.5%, compared to 11.9% and 4.8% for the indexes. In addition, you can check the fund’s top 5 holdings to find out its best picks for 2025. In its first-quarter 2025 investor letter, 1 Main Capital highlighted stocks such as Arvinas, Inc. (NASDAQ:ARVN). Arvinas, Inc. (NASDAQ:ARVN) is a clinical-stage biotechnology company. The one-month return of Arvinas, Inc. (NASDAQ:ARVN) was 4.78%, and its shares lost 77.71% of their value over the last 52 weeks. On May 1, 2025, Arvinas, Inc. (NASDAQ:ARVN) stock closed at $7.23 per share with a market capitalization of $527.728 million. 1 Main Capital stated the following regarding Arvinas, Inc. (NASDAQ:ARVN) in its Q1 2025 investor letter: "Arvinas, Inc. (NASDAQ:ARVN), a clinical-stage biotech company developing targeted protein degraders, is down more than 90% from its 2021 highs due to investor disappointment with its trials.Arvinas, Inc. (ARVN): Among Stocks Under $10 that Will Triple A biopharma executive in a meeting room discussing the clinical-stage of a new therapy. Arvinas, Inc. (NASDAQ:ARVN) is not on our list of 30 Most Popular Stocks Among Hedge Funds. As per our database, 32 hedge fund portfolios held Arvinas, Inc. (NASDAQ:ARVN) at the end of the fourth quarter, compared to 34 in the third quarter. While we acknowledge the potential of Arvinas, Inc. (NASDAQ:ARVN) as an investment, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns, and doing so within a shorter timeframe. If you are looking for an AI stock that is as promising as NVIDIA but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock. Story Continues In another article, we covered Arvinas, Inc. (NASDAQ:ARVN) and shared the list of stocks under $10 that will triple. In addition, please check out our hedge fund investor letters Q1 2025 page for more investor letters from hedge funds and other leading investors. READ NEXT: Michael Burry Is Selling These Stocks and A New Dawn Is Coming to US Stocks. Disclosure: None. This article is originally published at Insider Monkey. View Comments
Here are 1 Main Capital Partners’ Views on Arvinas (ARVN)
You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research.
Start Your Free Trial Now!Not sure where to invest today?
Kalkine’s latest research highlights three companies identified through in-depth analysis and market insights.
Explore these research reports to learn about companies currently being tracked by our analysts and make more informed investment decisions.
View 3 Research ReportsThis information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
Please wait processing your request...